NO330511B1 - Anvendelse av mikropartikler av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, og legemiddel erholdt derved - Google Patents
Anvendelse av mikropartikler av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, og legemiddel erholdt derved Download PDFInfo
- Publication number
- NO330511B1 NO330511B1 NO20012409A NO20012409A NO330511B1 NO 330511 B1 NO330511 B1 NO 330511B1 NO 20012409 A NO20012409 A NO 20012409A NO 20012409 A NO20012409 A NO 20012409A NO 330511 B1 NO330511 B1 NO 330511B1
- Authority
- NO
- Norway
- Prior art keywords
- microparticles
- drug
- paclitaxel
- treatment
- albumin
- Prior art date
Links
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 39
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 239000011859 microparticle Substances 0.000 title claims abstract description 13
- 108010088751 Albumins Proteins 0.000 title claims abstract description 8
- 102000009027 Albumins Human genes 0.000 title claims abstract description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 14
- 210000001367 artery Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001361 intraarterial administration Methods 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 208000031847 Carcinoma of the anal canal Diseases 0.000 description 3
- 208000002896 anal canal carcinoma Diseases 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000011127 radiochemotherapy Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001107A ITMI20001107A1 (it) | 2000-05-18 | 2000-05-18 | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012409D0 NO20012409D0 (no) | 2001-05-16 |
| NO20012409L NO20012409L (no) | 2001-11-19 |
| NO330511B1 true NO330511B1 (no) | 2011-05-09 |
Family
ID=11445079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012409A NO330511B1 (no) | 2000-05-18 | 2001-05-16 | Anvendelse av mikropartikler av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, og legemiddel erholdt derved |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6652884B2 (https=) |
| EP (1) | EP1155692B1 (https=) |
| JP (1) | JP2001354559A (https=) |
| KR (2) | KR20010105248A (https=) |
| CN (1) | CN1198609C (https=) |
| AT (1) | ATE267594T1 (https=) |
| AU (1) | AU781517B2 (https=) |
| BR (1) | BR0102040A (https=) |
| CA (1) | CA2345482A1 (https=) |
| DE (1) | DE60103453T2 (https=) |
| DK (1) | DK1155692T3 (https=) |
| ES (1) | ES2221874T3 (https=) |
| HU (1) | HU229909B1 (https=) |
| IL (1) | IL142674A0 (https=) |
| IT (1) | ITMI20001107A1 (https=) |
| MX (1) | MXPA01004980A (https=) |
| NO (1) | NO330511B1 (https=) |
| NZ (1) | NZ511201A (https=) |
| PT (1) | PT1155692E (https=) |
| RU (1) | RU2270003C2 (https=) |
| TR (1) | TR200101353A3 (https=) |
| ZA (1) | ZA200103755B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| CA2509365C (en) * | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| CN1925874B (zh) * | 2002-12-09 | 2014-12-17 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| KR20070114753A (ko) * | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| LT3311805T (lt) | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
| EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| BRPI0617663A2 (pt) * | 2005-10-21 | 2011-08-02 | Panacea Biotec Ltd | composições aperfeiçoadas para terapia de cáncer |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| KR101090505B1 (ko) * | 2008-12-30 | 2011-12-06 | 최은아 | 난담반을 포함하는 암 예방 및 치료용 조성물 |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| JP6387389B2 (ja) * | 2013-03-13 | 2018-09-05 | アブラクシス バイオサイエンス， エルエルシー | 小児充実性腫瘍の処置の方法 |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| WO2018037595A1 (ja) | 2016-08-26 | 2018-03-01 | 哲治 奥野 | 微小血管血流低減剤およびその利用 |
| TWI660728B (zh) | 2018-02-09 | 2019-06-01 | National Chiao Tung University | 胺基喹唑啉衍生物及其醫藥組合物與用途 |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| CN120919082A (zh) * | 2025-10-16 | 2025-11-11 | 天津医科大学总医院 | 一种负载蛋白药物的GelMA微球、制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| NZ262679A (en) | 1993-02-22 | 1997-08-22 | Vivorx Pharmaceuticals Inc | Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| PT1023050E (pt) * | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| CA2362338A1 (en) | 1998-07-30 | 2000-02-10 | Human Rt. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
-
2000
- 2000-05-18 IT IT2000MI001107A patent/ITMI20001107A1/it unknown
-
2001
- 2001-04-17 US US09/835,384 patent/US6652884B2/en not_active Expired - Lifetime
- 2001-04-18 IL IL14267401A patent/IL142674A0/xx active IP Right Grant
- 2001-04-19 NZ NZ511201A patent/NZ511201A/xx not_active IP Right Cessation
- 2001-04-20 AU AU38765/01A patent/AU781517B2/en not_active Expired
- 2001-04-24 JP JP2001126061A patent/JP2001354559A/ja active Pending
- 2001-04-27 DE DE60103453T patent/DE60103453T2/de not_active Expired - Lifetime
- 2001-04-27 DK DK01110509T patent/DK1155692T3/da active
- 2001-04-27 EP EP01110509A patent/EP1155692B1/en not_active Expired - Lifetime
- 2001-04-27 CA CA002345482A patent/CA2345482A1/en not_active Abandoned
- 2001-04-27 PT PT01110509T patent/PT1155692E/pt unknown
- 2001-04-27 ES ES01110509T patent/ES2221874T3/es not_active Expired - Lifetime
- 2001-04-27 AT AT01110509T patent/ATE267594T1/de active
- 2001-05-09 ZA ZA200103755A patent/ZA200103755B/xx unknown
- 2001-05-15 TR TR2001/01353A patent/TR200101353A3/tr unknown
- 2001-05-16 NO NO20012409A patent/NO330511B1/no not_active IP Right Cessation
- 2001-05-17 KR KR1020010026970A patent/KR20010105248A/ko not_active Ceased
- 2001-05-17 MX MXPA01004980A patent/MXPA01004980A/es active IP Right Grant
- 2001-05-17 RU RU2001113688/15A patent/RU2270003C2/ru active
- 2001-05-17 HU HU0102039A patent/HU229909B1/hu unknown
- 2001-05-18 CN CNB011192585A patent/CN1198609C/zh not_active Ceased
- 2001-05-18 BR BR0102040-4A patent/BR0102040A/pt not_active Application Discontinuation
-
2008
- 2008-09-26 KR KR1020080094590A patent/KR20080091747A/ko not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330511B1 (no) | Anvendelse av mikropartikler av paclitaxel stabilisert med albumin for fremstilling av et legemiddel for behandling av faste tumorer, og legemiddel erholdt derved | |
| EP2952184B1 (en) | Pharmaceutical formulation for treating pancreatic cancer | |
| JP2006524073A (ja) | 運搬促進デリバリー法による組織および腫瘍への液体の投与のための携帯用装置 | |
| AU2880500A (en) | Use of lipoic acid combination with ascorbic acid in the treatment of cancer | |
| Kapp et al. | Limitations of high dose intra-arterial 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas | |
| Jackson et al. | High dose intravenous vitamin C and long time survival of a patient with cancer of the head of the pancreas | |
| MX2011000036A (es) | Implante de octreotida que tiene un agente de liberacion. | |
| JP2018513130A (ja) | Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用 | |
| Guarnieri et al. | Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues | |
| Yu et al. | Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice | |
| CN120204218A (zh) | Aldometanib在制备预防和治疗免疫相关不良反应和疾病药物中的应用 | |
| RU2194541C1 (ru) | Способ комбинированного лечения больных местнораспространенным раком желудка | |
| CN109498547B (zh) | 一种平阳霉素局部注射制剂及其制备方法 | |
| HK1040368B (en) | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby | |
| Wakabayashi et al. | Intratumoral microinfusion of nimustine (ACNU) for recurrent glioma | |
| CN115089544A (zh) | 三氧化二砷缓释长效原位磷脂凝胶及其制备方法和用途 | |
| Chrousos et al. | Prevention of ocular toxicity of carmustine (BCNU) with supraophthalmic intracarotid infusion | |
| CN111407748A (zh) | 酪醇在制备治疗脑胶质瘤的药物中的应用 | |
| RU2515550C1 (ru) | Способ лечения катаракты у больных с псевдоэксфолиативным синдромом | |
| CN117281793A (zh) | 一种纳米药物及其制备方法和应用 | |
| CN101293086A (zh) | 一种镇痛消瘤药物及其制备方法 | |
| TW201938174A (zh) | 小分子褐藻醣膠用於製備放射線治療肺癌的增敏劑的用途 | |
| OA17078A (en) | New pediatric uses of cabazitaxel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |